KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Change in Accured Expenses (2017 - 2025)

Twist Bioscience (TWST) has disclosed Change in Accured Expenses for 7 consecutive years, with -$2.9 million as the latest value for Q3 2023.

  • On a quarterly basis, Change in Accured Expenses rose 77.61% to -$2.9 million in Q3 2023 year-over-year; TTM through Sep 2023 was -$1.1 million, a 85.2% increase, with the full-year FY2025 number at -$2.4 million, down 130.54% from a year prior.
  • Change in Accured Expenses was -$2.9 million for Q3 2023 at Twist Bioscience, down from $4.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $4.5 million in Q2 2023 to a low of -$12.9 million in Q3 2022.
  • A 5-year average of -$195052.6 and a median of $677000.0 in 2020 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 914.38% in 2019, then crashed 3588.24% in 2022.
  • Twist Bioscience's Change in Accured Expenses stood at $189000.0 in 2019, then soared by 258.2% to $677000.0 in 2020, then crashed by 105.02% to -$34000.0 in 2021, then plummeted by 3588.24% to -$1.3 million in 2022, then crashed by 131.1% to -$2.9 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Change in Accured Expenses are -$2.9 million (Q3 2023), $4.5 million (Q2 2023), and -$1.4 million (Q1 2023).